Challenging Myelopathy Cases

Semin Neurol
DOI: 10.1055/a-1985-0124

Rafid Mustafa

1   Department of Neurology, Mayo Clinic College of Medicine and Science, Rochester, Minnesota

,

Nicholas L. Zalewski

2   Department of Neurology, Mayo Clinic Arizona, Scottsdale, Arizona

,

1   Department of Neurology, Mayo Clinic College of Medicine and Science, Rochester, Minnesota

3   Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine and Science, Rochester, Minnesota

,

Neeraj Kumar

1   Department of Neurology, Mayo Clinic College of Medicine and Science, Rochester, Minnesota

› Author Affiliations Financial Support and Conflict of Interest Disclosure
R.M. reports no disclosures relevant to this manuscript.
N.L.Z. reports no disclosures relevant to this manuscript.
E.P.F. has served on advisory boards for Alexion, Genentech and Horizon Therapeutics. He has received speaker honoraria from Pharmacy Times. He received royalties from UpToDate. E.P.F. was a site primary investigator in a randomized clinical trial on inebilizumab in neuromyelitis optica spectrum disorder run by Medimmune/Viela-Bio/Horizon Therapeutics. E.P.F. has received funding from the NIH (R01NS113828). E.P.F. is a member of the Medical Advisory Board of the MOG project. E.P.F. is an editorial board member of the Journal of the Neurological Sciences and Neuroimmunology Reports. A patent has been submitted on DACH1-IgG as a biomarker of paraneoplastic autoimmunity.
N.K. reports no disclosures relevant to this manuscript.

留言 (0)

沒有登入
gif